ERBB2 and breast carcinoma: In BOLERO‐3, addition of everolimus to trastuzumab plus vinorelbine significantly prolongs progression‐free survival compared with placebo in patients with trastuzumab‐resistant and taxane‐pretreated, ErbB2‐positive, advanced breast cancer 40.